Vincamine, from an antioxidant and a cerebral vasodilator to its anticancer potential.
Anticancer potential
Antioxidant
Mechanisms of action
Vinblastine
Vincamine
Journal
Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298
Informations de publication
Date de publication:
07 09 2023
07 09 2023
Historique:
received:
31
05
2023
revised:
06
08
2023
accepted:
07
08
2023
pmc-release:
07
09
2024
medline:
21
8
2023
pubmed:
15
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Vincamine is a naturally occurring indole alkaloid showing antioxidant activity and has been used clinically for the prevention and treatment of cerebrovascular disorders and insufficiencies. It has been well documented that antioxidants may contribute to cancer treatment, and thus, vincamine has been investigated recently for its potential antitumor activity. Vincamine was found to show cancer cell cytotoxicity and to modulate several important proteins involved in tumor growth, including acetylcholinesterase (AChE), mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB), nuclear factor erythroid 2-related factor 2 (Nrf2), and T-box 3 (TBX3). Several bisindole alkaloids, including vinblastine and vincristine and their synthetic derivatives, vindesine, vinflunine, and vinorelbine, have been used as clinically effective cancer chemotherapeutic agents. In the present review, the discovery and development of vincamine as a useful therapeutic agent and its antioxidant and antitumor activity are summarized, with its antioxidant-related mechanisms of anticancer potential being described. Also, discussed herein are the design of the potential vincamine-based oncolytic agents, which could contribute to the discovery of further new agents for cancer treatment.
Identifiants
pubmed: 37579526
pii: S0968-0896(23)00287-0
doi: 10.1016/j.bmc.2023.117439
pmc: PMC10530545
mid: NIHMS1925645
pii:
doi:
Substances chimiques
Vincamine
996XVD0JHT
Vasodilator Agents
0
Antioxidants
0
Acetylcholinesterase
EC 3.1.1.7
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
117439Subventions
Organisme : NCI NIH HHS
ID : P01 CA125066
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Acta Crystallogr. 1966 Sep 10;21(3):322-31
pubmed: 5953637
Acta Crystallogr B Struct Sci Cryst Eng Mater. 2013 Jun;69(Pt 3):249-59
pubmed: 23719469
Expert Opin Ther Pat. 2015 May;25(5):583-93
pubmed: 25887337
Am J Transl Res. 2018 Jul 15;10(7):2195-2204
pubmed: 30093956
Cancer Cell Int. 2022 Jun 2;22(1):206
pubmed: 35655306
Urol Oncol. 2002 Jul-Aug;7(4):159-66
pubmed: 12474532
Dis Colon Rectum. 2022 Aug 1;65(8):1015-1024
pubmed: 34856584
J Glaucoma. 1999 Apr;8(2):117-23
pubmed: 10209728
Life Sci. 2021 May 1;272:119224
pubmed: 33610575
Eur J Med Chem. 2019 Sep 15;178:687-704
pubmed: 31228811
Epilepsy Behav. 2021 Jun;119:107988
pubmed: 33957389
Mol Cancer. 2022 Jan 26;21(1):30
pubmed: 35081965
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Free Radic Biol Med. 2011 Sep 1;51(5):1068-84
pubmed: 21683786
Apoptosis. 2012 Oct;17(10):1120-30
pubmed: 22729609
Acta Crystallogr Sect E Struct Rep Online. 2011 Nov;67(Pt 11):o2867
pubmed: 22219907
Pharmacology. 2021;106(1-2):37-44
pubmed: 32294652
Brain Res. 2021 Mar 2;:147399
pubmed: 33662337
J Pharm Sci. 2016 Dec;105(12):3626-3633
pubmed: 27789032
Oxid Med Cell Longev. 2016;2016:4350965
pubmed: 26998193
Biomed Pharmacother. 2022 Jul;151:113112
pubmed: 35598366
Mini Rev Med Chem. 2022;22(2):200-212
pubmed: 34254913
Eur J Pharmacol. 2018 Jan 15;819:30-34
pubmed: 29183836
Med Res Rev. 2005 Nov;25(6):737-57
pubmed: 16158388
Anticancer Drugs. 2021 Aug 1;32(7):727-733
pubmed: 33735117
Free Radic Biol Med. 2012 May 1;52(9):2013-37
pubmed: 22391222
Molecules. 2022 Feb 18;27(4):
pubmed: 35209172
J Biochem Mol Toxicol. 2022 Jul;36(7):e23046
pubmed: 35315168
J Investig Med. 2022 Aug;70(6):1358-1364
pubmed: 35580917
Front Oncol. 2021 Feb 05;10:597601
pubmed: 33614484
Antioxidants (Basel). 2023 Mar 12;12(3):
pubmed: 36978952
Evid Based Complement Alternat Med. 2015;2015:654098
pubmed: 26457112
Chemistry. 2023 Aug 1;29(43):e202300981
pubmed: 37099319
Mol Cells. 2023 Mar 31;46(3):142-152
pubmed: 36927604
Arch Toxicol. 2019 May;93(5):1417-1431
pubmed: 31020375
Cancer Metastasis Rev. 2023 Mar;42(1):49-85
pubmed: 36701089
Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):585-597
pubmed: 27825853
Fitoterapia. 2020 Jun;143:104558
pubmed: 32198108
Cell Rep Med. 2023 May 16;4(5):101019
pubmed: 37060903
J Nat Prod. 2022 Mar 25;85(3):702-719
pubmed: 35213158
Biochem Soc Trans. 2015 Aug;43(4):621-6
pubmed: 26551702
J Drug Target. 2007 Aug-Sep;15(7-8):475-86
pubmed: 17671894
Cancer Invest. 1997;15(5):475-90
pubmed: 9316630
Cancers (Basel). 2010 Apr 13;2(2):483-97
pubmed: 24281078
Exp Eye Res. 2014 Oct;127:49-58
pubmed: 25041941
J Endocrinol. 2019 Feb 1;240(2):195-214
pubmed: 30400036
Arch Toxicol. 2020 Mar;94(3):651-715
pubmed: 32180036
Redox Biol. 2023 Jun;62:102659
pubmed: 36917900
Curr Med Chem. 2018;25(14):1650-1662
pubmed: 28464783
J Hematol Oncol. 2022 Sep 14;15(1):133
pubmed: 36104717
Int Immunopharmacol. 2022 Jul;108:108773
pubmed: 35453074
Expert Opin Drug Saf. 2011 Jul;10(4):645-53
pubmed: 21524237
J Neurosci Res. 2023 Aug;101(8):1275-1288
pubmed: 36977650
Oncotarget. 2017 Sep 7;8(46):80315-80324
pubmed: 29113305
Surg Endosc. 2021 Jun;35(6):2750-2758
pubmed: 32556753
Front Pharmacol. 2021 May 31;12:664022
pubmed: 34135755
Eur J Med Chem. 2021 Nov 5;223:113652
pubmed: 34161865
J Biomol Struct Dyn. 2023 Apr;41(7):3025-3041
pubmed: 35253621
Molecules. 2023 Feb 03;28(3):
pubmed: 36771154
Biotechnol Adv. 2020 Jan - Feb;38:107337
pubmed: 30633954
Cell Mol Biol (Noisy-le-grand). 2022 Jul 31;68(7):14-21
pubmed: 36495525
Phytochemistry. 2022 Nov;203:113384
pubmed: 36007666
Bioorg Med Chem. 2010 Jun 15;18(12):4415-21
pubmed: 20576577
Autoimmun Rev. 2023 May;22(5):103308
pubmed: 36822387
Food Chem Toxicol. 2018 Jan;111:114-124
pubmed: 29129665
PLoS One. 2013 Dec 09;8(12):e82509
pubmed: 24349299
Int Immunopharmacol. 2023 Jun;119:110236
pubmed: 37148772
J Food Biochem. 2020 Mar;44(3):e13145
pubmed: 31960481
Chem Sci. 2021 Jan 20;12(9):3264-3269
pubmed: 34164095
Ageing Res Rev. 2023 Feb;84:101819
pubmed: 36526257
Eur J Pharmacol. 2019 Jan 15;843:233-239
pubmed: 30496743
Biomed Pharmacother. 2020 Mar;123:109769
pubmed: 31846839
ChemMedChem. 2016 Nov 7;11(21):2392-2397
pubmed: 27677525
Life Sci. 2018 Jun 1;202:78-88
pubmed: 29626531
Thorac Cancer. 2015 Jul;6(4):390-8
pubmed: 26273392
Neurochem Int. 2023 May;165:105509
pubmed: 36907516
Bioorg Med Chem Lett. 2018 Sep 15;28(17):2816-2826
pubmed: 30122223
Bioorg Med Chem Lett. 2013 Nov 1;23(21):5865-9
pubmed: 24055047
J Org Chem. 1968 Mar;33(3):1055-9
pubmed: 5639341
Adv Cancer Res. 2021;152:1-66
pubmed: 34353435
J Cancer Res Clin Oncol. 2004 Nov;130(11):627-35
pubmed: 15340840
Curr Top Med Chem. 2015;15(15):1491-500
pubmed: 25877096
J Med Chem. 2020 Dec 24;63(24):15410-15448
pubmed: 33289552
Nutr Cancer. 2017 Nov-Dec;69(8):1099-1104
pubmed: 29043851
J Exp Clin Cancer Res. 2020 Dec 24;39(1):289
pubmed: 33357230
Molecules. 2022 May 09;27(9):
pubmed: 35566385
Life Sci. 2020 Oct 1;258:118186
pubmed: 32768586
EXCLI J. 2021 Mar 04;20:550-561
pubmed: 34121971
Bioorg Chem. 2021 Feb;107:104626
pubmed: 33450545